Gedeon Richter Plc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Gedeon Richter Plc.
New treatments for congenital adrenal hyperplasia and relapsing forms of multiple sclerosis are among five drugs recommended for pan-EU approval this month. In addition, harmonized EU advice has been issued for Celltrion’s monoclonal antibody COVID-19 treatment.
An new $2.1bn incentive scheme for formulations follows on from an earlier scheme for APIs in India. Experts weigh in on the likelihood of industry participation and whether this $3bn push will result in $41bn of incremental sales for the industry while strengthening supply chains in a post-COVID world.
Following an INR69bn incentive scheme for APIs, the Indian government has come up with an INR150bn scheme for formulations and more. Will this $3bn push prove to be the one that companies like Sun Pharma and Aurobindo, currently at 36 and 48 respectively in Scrip 100 rankings, need to break into the top league?
Hungary’s Gedeon Richter achieved record results in 2020, driven by a near trebling of the firm’s group operating profit and rising sales. Management once again had much to say on the company’s biosimilar ambitions.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- PregLem Holding SA
- Richter Gedeon Vegyeszeti Gyar Nyrt
- Richter-Helm BioTec GmbH
- FINOX Biotech
- Finox AG